Logo
x

Search category

Subscribe Now

Late-line Treatment

GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer

GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer

  • October 24, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.